U.S. Markets closed

Pressure BioSciences, Inc. (PBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
6.25+0.11 (+1.79%)
At close: 3:18PM EDT
People also watch
  • reverse split soon.
  • Wow - just wow! Great price movement today... to the moon baby!!
  • someone is buying and some are selling, activity keeps it listed so no delisting?
  • Pressure BioSciences Receives 2017 North American Excellence Award: "Best New Instrument for Sample Preparation"

    Barocycler 2320EXTREME Honored as Superior Instrument for Sample Preparation by Leading Publication for CEOs, Top-tier Management, and Key Decision Makers Across North America

    SOUTH EASTON, MA--(Marketwired - Mar 1, 2017) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that its Barocycler 2320EXTREME ("2320EXT") has been named the "Best New Instrument for Sample Preparation 2017" by Corporate America News ("Corp America") as part of the publication's 2017 North American Excellence Awards.

    With a subscription list of more than 135,000 business and professional service providers, Corp America is a leading magazine in the U.S business market. The magazine's annual North American Excellence Awards honor companies and individuals who tirelessly work to drive innovation and exhibit true passion for their work.

    The award-winning, next-generation Barocycler 2320EXT is the latest addition to PBI's Barocycler family. It is a compact, bench-top instrument offering many advanced features and benefits. These and other additions have already positioned the Barocycler 2320EXT as an instrument of choice for life science key opinion leaders ("KOLs") worldwide, when preparing protein samples for analysis.

    Dr. Nate Lawrence, Vice President of Marketing and Sales for PBI, said: "We are honored to have been selected for this prestigious award. It was just eight months ago when we launched this next-generation Barocycler instrument, the 2320EXT. Since then, the instrument has been purchased by key scientists in academic, government, biotech and pharma labs worldwide, including institutions involved in the Cancer Moonshot Initiative. We believe this award affirms the significant potential of the Barocycler 2320EXT."

    ProCan, a cancer research initiative located in the Children's Medical Research Institute near Sydney Australia, and a Cancer Moonshot collaborator, purchased three Barocycler 2320EXTs in June 2016. At the time of their purchase, Professor Phil Robinson, co-head of ProCan, said: "Patient tumor samples can be pretty tiny and very heterogeneous, but the use of PCT in sample preparation allows researchers to analyze tissue samples as small as those provided by needle biopsies. So you can use incredibly small amounts of tissue, reliably digest them in a couple of hours, and get large amounts of information with the Barocycler 2320EXT."

    Professor Ruedi Aebersold, a world-renowned protein chemist who recently upgraded to the Barocycler 2320EXT, emphasized the importance of sample preparation in the article. Dr. Aebersold said: "Not only do we need to consider the method of analyzing the proteome, but we must also recognize that the method of sample preparation used to optimize protein extraction & digestion is equally as important."

    Dr. Lawrence commented: "It is the support of KOLs like Professors Robinson and Aebersold that we believe helped convince the panel of judges that the Barocycler 2320EXT deserved to win the 2017 North American Excellence Award for Best New Sample Preparation Instrument."

    PBI President and CEO Richard T. Schumacher was interviewed by the magazine upon selection of the award. In a four-page article, Mr. Schumacher provided an in-depth overview of PBI's patented PCT technology and its unique advantages, the Company's history of innovation and growth, its large market opportunity, additional features and benefits of the 2320EXT, the recent co-marketing agreement with global life sciences leader SCIEX, and his expectations that significant growth is on the horizon.

    To view the full article, visit http://www.corporateamericanews.com/2017-north-american-excellence-awards. A picture of the award-winning 2320EXT is on the inside front cover of the magazine and the article starts on page 8.

    About Pressure BioSciences, Inc.
    Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.

    Forward Looking Statements
    Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

    For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

    Please visit us on Facebook, LinkedIn, and Twitter

    Investor Contacts:
    Richard T. Schumacher
    President & CEO
    Pressure BioSciences, Inc.

    Nathan P. Lawrence, Ph.D.
    VP of Marketing and Sales
    (508) 230-1828 (T)

  • Nice price action today! Let's hope this is the bottom and the rebound is strong!
  • Pressure BioSciences Ramps Up Commercialization of Next-Generation Instrument with CE Marking -- SECFilings.com

    REDONDO BEACH, CA--(Marketwired - Feb 9, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing Pressure BioSciences Inc.'s (OTCQB: PBIO) recently announced CE Marking for the company's newest device, the Barocycler 2320EXT.

    The life sciences industry has rapidly evolved over the past decade. For example, newly developed proteomic and genomic analysis techniques have helped researchers improve the detection, treatment, and prevention of cancers and other serious diseases. New programs, such as the Cancer Moonshot Initiative, are designed to invest in these new technologies to accelerate the research and development of new treatment options for patients, as well as new preventive strategies.

    Pressure Bio's Pressure Cycling Technology improves upon the sample preparation process by subjecting cells to alternating cycles of hydrostatic pressure between ambient and high/ultra levels. This enables researchers to quickly, safely, and reproducibly control the cell lysis (breakage) process by effectively squeezing out important cellular components with minimal or no damage whatsoever -- like squeezing things out of a sponge.

    Pressure Bio recently launched the Barocycler 2320EXTREME -- the first major update of its flagship PCT-based sample preparation instrument in years. This release followed years of extensive user feedback. The compact, benchtop instrument offers many features and benefits not found in its predecessor, including data logging options, user-level security, computer-operated control with touch screen programming, and the ability to customize multiple pressure cycling parameters. These new features and benefits could greatly expand the universe of potential users worldwide.

    The company recently announced that it secured a CE Marking for the Barocycler 2320EXT -- a key milestone that enables it to sell the device throughout the entire European Economic Area, which includes 31 countries. Since 1985, the CE Mark has been required for products in 24 different categories sold within the European Economic Area, with each product falling under various directives that determine specific requirements designed to meet safety, health, and/or environmental requirements.

    Pressure Bio recently signed agreements with several distribution partners throughout Europe that could open the door to near-term revenue. In addition, the company is entering the second year of its co-marketing agreement with SCIEX -- a global provider of lab instrumentation with a large presence in Europe. Many key opinion leaders, like Professor Ruedi Aebersold, have also purchased the product, which has demonstrated its usefulness in advanced research operations.

    Please follow the link to read the full article: http://analysis.secfilings.com/articles/150-pressure-biosciences-ramps-up-commercialization-of-next-generation-instrument-with-ce-marking

    About SECFilings.com

    Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


    Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

    Paul Archie

    Copyright © 2017 Marketwired. All Rights Reserved

  • Great news today: http://finance.yahoo.com/news/pressure-biosciences-achieves-ce-marking-145258039.html

    Anyone have thoughts on what this does to go-forward numbers / share price, etc.?

    Pressure BioSciences Achieves CE Marking for its Next Generation Sample Preparation Instrument, the Barocycler 2320EXTREME
    Pressure BioSciences, Inc. , a leader in the development and sale of broadly enabling, pressure cycling technology -based sample preparation solutions to the worldwide life sciences industry, today announced ...
  • Jonathan, didn't Schumacher--excuse the spelling if I'm wrong--hint at cash flow break even pretty soon on the last call?
  • Riding to sub 10 cent level where it will be scooped up prior to bankruptcy for 5 - 8 cants a share. A shame really. There was some real potential here. Someone will take this technology and ride it high, but it's going to require deep pockets and patience. Any small retail investors such as myself will get left holding nothing. Oh well. There's always going to be winners and losers when dealing with high tech. We (the shareholders) have lost this one.
  • anytime you see ads on tv and internet to buy a stock, run away. pbio shafted so many.
  • Another Conference ?? LMAO
  • What a catastrophe PBIO has unloaded on shareholders... REVERSE SPLIT coming, stock being blasted due to S1...PBIO management simply BAGGED SHAREHOLDERS!!! Strictly amateur hour at PBIO
  • So , Where are the pumpers??
  • Soon to trade under a penny….

    assets 2 mil
    liabilities 15 mil
    shares 31 mill
    What does this equal " Garbage "
  • "Pressure BioSciences, Inc. Well Positioned to Play Important Role in US's $1.8 Billion "Cancer Moonshot" Initiative Bill Signed Into Law Earlier this Week Offers the Potential to Completely Transform Cancer Research"
  • Some investors sell for losses this time off year if they are in it for the short term. Was a great day with share volume, first trade was 200,000 at the buy this AM.
  • Pressure Biosciences CEO On Its Beaten Down Stock: 'We Can Now Begin To Focus On The Area That Is Most Important'

    Pressure Biosciences Inc (OTC: PBIO) is a nano cap company focused on biological sample preparation processes (see the challenges in the industry here). The stock experienced plenty of volatility this year, but is ultimately down 13.2 percent since January and about 24.5 percent in the last six months.

    Benzinga had the chance to chat with the company’s CEO Richard T. Schumacher, who shared some insights into the stock, the company and its growth initiatives.

    A Beaten Down Stock

    Questioned about Pressure Biosciences’ stock’s recent underperformance, the exec voiced, “I think the stock is significantly undervalued. When the stock was in the $0.50 per share range just three months ago, we thought the same.”

    “The stock is at a level now where it was six months ago, when we had $3 million of toxic debt, no next-generation instruments, no line of credit, and no deal with a leading mass spectrometry company in the world,” he said, referencing some of the milestones described below.

    Recent Milestones

    The chief executive went on to point out a few milestones investors should take into account when considering an investment. These include:

    The closing of the sale of $610,000 of its common stock in a PIPE transaction, at a premium to the market.
    The elimination of almost $3 million in floorless debt.
    The opening of a $2 million, unsecured line of credit under what they have defined as “very reasonable terms for PBI's shareholders.”
    This makes the company “financially secure” for the first time in several quarters, Schumacher assured. “What this means to us is that we can begin to focus on the area that we think is most important: sales and marketing.” So, what the company is doing is assembling a small sales team.

    In addition, Pressure Biosciences closed a co-marketing agreement with instrumentation provider SCIEX — a wholly owned subsidiary of the Danaher Corporation (NYSE: DHR). “We now work hand in glove with SCIEX, so we don’t need sales people to support that,” he expounded.

    Companies like Thermo Fisher Scientific Inc. (NYSE: TMO), Agilent Technologies Inc (NYSE: A), Bruker Corporation (NASDAQ: BRKR) and Waters Corporation (NYSE: WAT) all make mass spectrometers, Schumacher went on to explain.

    “Our system sits in front of a mass spectrometer and –we think- makes the mass spectrometer results better,” he assured. “So, now that we’ve received equity and debt financing [...] we are going to build a sales force focused on going out and getting customers, primarily those who have a mass spectrometer, because of the 100+ papers that have been published, most of them –although not all, deal with using our system in front of a mass spectrometer and getting better results. So that’s our low hanging fruit.”

    Looking Ahead

    When asked about a possible uplisting of the stock to the Nasdaq exchange next year, Schumacher responded, “we understand, as a company, that it’s important to get on a national exchange, and we are looking into the possibility of an uplist. It is a goal of ours to uplist the company in the near future.”

    Richard T. Schumacher owns about 10 percent of the company’s shares outstanding, as disclosed during the interview.
  • PBIO getting ready for take off. All passengers please be seated and buckle your seat belts, enjoy the entertainment provided by PBIO on this flight.
  • PBIO: Update on Third Quarter Financials
    Zacks Small Cap Research
    November 21, 2016

  • Alert about $PBIO on http://thehottip.com/?s=PBIO